Crossmark

Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status

Crossref DOI link: https://doi.org/10.1038/s41409-021-01380-0

Published Online: 2021-06-21

Published Print: 2021-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shimomura, Yoshimitsu https://orcid.org/0000-0003-1018-9508
Hara, Masahiko

Hirabayashi, Shigeki

Kondo, Tadakazu https://orcid.org/0000-0002-8959-6271
Mizuno, Shohei https://orcid.org/0000-0002-4405-8808
Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Mukae, Junichi

Kawakita, Toshiro

Fukuda, Takahiro

Kanda, Yoshinobu https://orcid.org/0000-0002-4866-9307
Ota, Shuichi https://orcid.org/0000-0002-3631-244X
Ozawa, Yukiyasu

Eto, Tetsuya

Maruyama, Yumiko

Tanaka, Masatsugu

Nakano, Nobuaki https://orcid.org/0000-0001-9826-7616
Kimura, Takafumi

Ichinohe, Tatsuo https://orcid.org/0000-0002-0393-4066
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Yanada, Masamitsu https://orcid.org/0000-0003-1602-9775
License Information

Text and Data Mining valid from 2021-06-21

Version of Record valid from 2021-06-21
More Information

Article History

Received: 28 March 2021

Revised: 21 May 2021

Accepted: 10 June 2021

First Online: 21 June 2021

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below